NCT03183219

Safety and Efficiency of γδ T Cell Against Liver Cancer

γδ T Cell Immunotherapy for Treatment of Liver Cancer

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Fuda Cancer Hospital, Guangzhou · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

In this study, effects of γδT cells on human Liver Cancer in combination with tumor reducing surgery, for example, cryosurgery going to be investigated.

Detailed description

A liver tumor will be removed using tumor reducing surgery such as cryosurgery.PBMC of the patient will be separated from peripheral blood. After making them potential cancer killer γδ T Cell and DC-CIK, they will be infused to the patients as an immunotherapy treatment. NOTE: Originally, our designed proposal was to use autologous PBMCs from cancer patients to ex vivo expand Vγ9Vδ2-T cells, and then perform adoptive transfer therapy. However, PBMCs of majority of cancer patients could not be effectively expanded, including cell number, cell purity and cell function could not meet the requirements of reinfusion. Meanwhile, those patients could not tolerate 100ml of blood drawing for culture every 2 \~ 3 weeks. Therefore, we submitted new clinical study application to the ethical committee of the Fuda Hospital affiliated with Jinan University (Guangzhou, PR. China) by changing the autologous protocol with the allogeneic protocol. After the allogeneic protocol was approved, we adapted allogeneic cells instead of autologous in our subsequentially clinical study.

Conditions

• Liver Cancer

Interventions

Type	Name	Description
PROCEDURE	Cryosurgery or IRE surgery	Cryosurgery or IRE surgery will be used in local tumor
BIOLOGICAL	γδ T cell	γδ T cells will be used against Liver Cancer
OTHER	γδ T cells/ A Cryosurgery or IRE	Combination γδ T cell and Cryosurgery or IRE surgery will be used in Liver Cancer

Timeline

• Start date: 2017-06-15
• Primary completion: 2018-01-15
• Completion: 2019-06-15
• First posted: 2017-06-12
• Last updated: 2020-07-13

Locations

1 site across 1 country: China